Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 20Ureteral Neoplasms 7Urologic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Urogenital Neoplasms 2Urethral Neoplasms 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 4lenvatinib 3Magnetic Resonance Spectroscopy 3Specimen Handling 2Nivolumab 2Epirubicin 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1anlotinib 1amivantamab 1abemaciclib 1Tablets 1Surveys and Questionnaires 1Standard of Care 1Radiosurgery 1Pemetrexed 1Observation 1Ipilimumab 1Imatinib Mesylate 1Glutamate Carboxypeptidase II 1Cyclophosphamide 1Combined Modality Therapy 1Carboplatin 1CTLA-4 Antigen 1Blood Specimen Collection 1BMS-906024 168Ga-DKFZ-PSMA-11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Adenoid Cystic × enfortumab vedotin × 1 year × Clear all
NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
34 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡